Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072319
Status:
COMPLETED
Last Update Posted:
2013-03-04
First Post:
2003-11-04
Brief Title:
Neoadjuvant or Adjuvant Epirubicin Cyclophosphamide and Paclitaxel in Treating Women With Stage I Stage II or Stage III Breast Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Organization Data
Organization:
Memorial Sloan Kettering Cancer Center
Class:
OTHER
Study ID:
03-092
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Amgen | INDUSTRY |
| National Cancer Institute NCI | NIH |
| Pharmacia | INDUSTRY |